Aim: We present results of a multicentre observational study demonstrating the use of a lyophilized amniotic membrane in the treatment of diabetic foot ulcerations, in addition to standard care of diabetic foot (offloading, revascularisation procedures etc). Method: 8 diabetic foot clinics enrolled from 1 to 13 patients with long-lasting diabetic ulcerations, totally 57 patients presenting 67 ulcers (5 patients had multiple ulcers). Amnioticmembrane was applied at every ulcer in 1week intervals. All patients obtained 2-5 applications and we observed the process of wound size change (measured by software Electreasure). Last visit was held 2 weeks after last application. Results / Discussion: 57 diabetic patients (mean age 63.6 years, 8 women = 14%, 9 type 1 diabetes = 16%) with HbA1c mean value 57 mmol/mol, 61% with normal kidney function. All patients with significant ischemia underwent revascularization procedures before starting the treatment with amniotic membrane. All of them used standard offloading therapy (crutches, wheelchairs, halfshoes, orthoses etc). Most from 67 defects were localized at plantar part of foot (10% at plantar surface of toes, 60% at metatarsal heads, 16% at heel). The mean wound area before was 6.47 cm2, 2 weeks after last application 1.73 cm2. 39% of all ulcers healed completely, 49% reduced their size significantly (mean size reduction 77% of area, from 53 to 98%), in 9% the wound size stayed unchanged and only in 2 (3%) patients the wound was worse than before. Conclusion: The application of freeze-dried human amniotic membrane could significantly help in the treatment of chronic diabetic ulceration -- could result in complete healing or significant reduction of the wound size during 3-6 weeks of therapy.